What is tenosynovial giant cell tumour?
Tenosynovial giant cell tumour (TGCT) is a rare tumour that grows from the lining of joints, bursae and tendon sheaths (the synovium). It is not cancer: it almost never spreads to other parts of the body. It can, however, grow into and damage the joint or tendon where it starts.
There are two main forms. The localised type forms a single, firm lump, most often on a finger or the hand. The diffuse type spreads through the lining of a whole joint, most often the knee, and was previously called pigmented villonodular synovitis (PVNS).
TGCT mostly affects young and middle-aged adults. It causes swelling, pain and stiffness, and in large joints it can lead to repeated bloody swelling and, over time, arthritis.
The tumour is driven by a gene change that makes a small number of cells overproduce a signal called CSF1. This signal attracts many inflammatory cells, which make up most of the tumour.
The main treatment is surgery. The diffuse type often comes back, and for people who are not helped by surgery, tablets that block the CSF1 receptor, such as vimseltinib and pexidartinib, can shrink the tumour and improve symptoms.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Benign but locally aggressive tumour of joint and tendon-sheath lining |
| How common | Localised type: about 30-40 per million people a year; diffuse type: about 4-5 per million |
| Typical age | Mostly 20-50 |
| Sex | Slightly more common in women |
| Main sites | Localised: fingers, hand, wrist, foot. Diffuse: knee (about 70%), hip, ankle, elbow, shoulder |
| Key gene change | CSF1 rearrangement, often COL6A3::CSF1 |
| Spread | Local growth into bone, tendons and soft tissue; spread to other organs is extremely rare |
| Main treatments | Surgery; radiotherapy in selected cases; CSF1R inhibitor tablets |
| Outlook | Normal life expectancy; diffuse type often recurs and can damage the joint |
2. Types of TGCT
| Feature | Localised TGCT | Diffuse TGCT |
|---|---|---|
| Older names | Giant cell tumour of tendon sheath; nodular tenosynovitis | Pigmented villonodular synovitis (PVNS) |
| Typical site | Fingers and hand; less often foot, ankle, knee | Knee, hip, ankle |
| Appearance | A single, well-defined nodule | Many nodules and finger-like growths lining the joint |
| Recurrence after surgery | About 5-15% | About 30-50% or more |
| Effect on the joint | Usually little | Can cause cartilage and bone damage and arthritis |
Malignant TGCT is extremely rare. It can arise on its own or in a long-standing TGCT and behaves like a sarcoma.
3. Causes and risk factors
| Factor | Notes |
|---|---|
| CSF1 gene rearrangement | A chromosome swap in a small number of tumour cells causes high levels of CSF1; these cells attract many macrophages and giant cells (a “landscape effect”) |
| Injury | Sometimes reported before diagnosis, but not proven to cause it |
| Inheritance | Not inherited |
| Lifestyle | No known lifestyle cause |
4. How does it look?
4.1 On the body
| Type | What it looks or feels like |
|---|---|
| Localised, finger or hand | A firm, rubbery, painless lump, usually 0.5-4 cm, on the palm side of a finger, close to a joint |
| Localised, large joint | A lump in or near the knee or ankle, sometimes causing locking |
| Diffuse | A swollen, warm, puffy joint, often the knee, with fluid and a boggy feel |
| Skin | Usually normal over the lump |
4.2 On scans
| Test | Typical findings |
|---|---|
| X-ray | Often normal; may show soft-tissue swelling or small, well-defined bone erosions on both sides of a joint |
| Ultrasound | A solid lump next to a tendon, or thickened joint lining |
| MRI | The key test. Areas of very low signal from iron (haemosiderin) that “bloom” on gradient-echo images; shows the full extent of disease |
4.3 At surgery and under the microscope
| Feature | What is seen |
|---|---|
| Colour | Yellow-brown or rusty, from iron deposits |
| Joint fluid | Often brownish or bloody |
| Cells | A mix of small round cells, foamy macrophages, multinucleated giant cells and iron-laden cells |
| Stains and genetics | CSF1 expression in a minority of cells; CSF1 rearrangement on FISH or sequencing in many cases |
Because the localised type often looks like a ganglion or a simple lump, many people have it for years before it is removed. The diffuse type is often first thought to be a sports injury, a torn cartilage or arthritis, which can delay diagnosis until an MRI is done.
5. Symptoms
5.1 Localised type
| Symptom | Notes |
|---|---|
| Painless lump | The most common sign, on a finger, hand, foot or ankle |
| Slow growth | Over months or years |
| Mild discomfort | When the lump is pressed or knocked |
| Stiffness or numbness | If the lump presses on a tendon or nerve |
| Locking or catching | When a nodule sits inside the knee |
5.2 Diffuse type
| Symptom | Notes |
|---|---|
| Joint swelling | Often the knee; may come and go |
| Pain | Aching, often worse with activity |
| Stiffness | Reduced range of movement |
| Warmth | The joint may feel warm |
| Repeated bloody joint swelling | Brown or bloody fluid when the joint is drained |
| Limp | With knee, hip or ankle disease |
| Arthritis | Long-term damage to cartilage and bone |
5.3 When to see a doctor
See a doctor for a lump that keeps growing, a joint that swells repeatedly without a clear cause, or long-lasting pain and stiffness in one joint. A young adult with a swollen knee that keeps coming back, especially with bloody fluid, should have an MRI scan.
6. Diagnosis
| Test | Why it is done |
|---|---|
| Examination | Checks the lump, joint swelling and movement |
| MRI | Confirms the typical appearance and maps the disease, which is vital for planning surgery |
| Joint aspiration | Brown or bloody fluid supports the diagnosis |
| Biopsy | Confirms the diagnosis if MRI is not typical; may be done during arthroscopy |
| Pathology review | Ideally at a sarcoma or specialist orthopaedic centre |
Several conditions can look similar on MRI or examination.
| Condition | How it differs |
|---|---|
| Ganglion cyst | Fluid-filled; transparent on ultrasound |
| Haemophilic joint disease | Also has iron in the joint, but in people with a bleeding disorder |
| Rheumatoid or other arthritis | Usually affects several joints, with blood test changes |
| Synovial sarcoma | A malignant tumour that may lie near a joint; looks different on MRI and biopsy |
| Lipoma arborescens | Fatty growths of the joint lining |
7. Treatment
Treatment aims to relieve symptoms, preserve joint function and avoid repeated, damaging surgery. Decisions are best made by a specialist team.
7.1 Localised TGCT
| Treatment | Notes |
|---|---|
| Surgical removal | The standard treatment, open or arthroscopic; recurrence is uncommon after complete removal |
| Watchful waiting | Reasonable for a small lump without symptoms |
7.2 Diffuse TGCT
| Treatment | What it involves | Notes |
|---|---|---|
| Synovectomy | Removal of the diseased joint lining, by arthroscopy or open surgery, sometimes front and back of the knee | The main treatment; recurrence is common |
| External beam radiotherapy | Low-dose radiotherapy after surgery | Considered for repeated recurrence or incomplete removal |
| Radiosynovectomy | Injection of a radioactive substance, such as yttrium-90, into the joint | Used in some centres |
| CSF1R inhibitors | Tablets that block the CSF1 receptor | For tumours that cause symptoms and are not suitable for surgery |
| Joint replacement | For joints badly damaged by arthritis | Also removes much of the disease |
| Active surveillance | Regular review | When symptoms are mild |
7.3 CSF1R inhibitor drugs
CSF1R inhibitors block the signal that draws inflammatory cells into the tumour. In trials, they shrank tumours and improved pain, stiffness and range of movement in many patients. They are usually reserved for people in whom surgery would cause serious loss of function or has already failed.
| Drug | Evidence | Notes |
|---|---|---|
| Vimseltinib | MOTION phase 3 trial: tumour response in 40% versus 0% with placebo at 25 weeks | Approved in the USA and the EU |
| Pexidartinib | ENLIVEN phase 3 trial: response in 39% versus 0% with placebo | Approved in the USA with liver monitoring; not approved in the EU |
| Pimicotinib | MANEUVER phase 3 trial showed benefit over placebo | Approved in China; under review in the USA and the EU |
| Imatinib | Used off-label in some centres | Older drug with smaller studies |
Symptoms often return if the drug is stopped, so treatment may continue for a long time.
For most people, the choice is not between “cure” and “no cure”, as TGCT does not threaten life. The aim is the best balance between controlling symptoms, protecting the joint and avoiding treatment harms.
8. Side effects of treatment
| Treatment | Possible effects |
|---|---|
| Surgery | Pain, stiffness, swelling, infection, wound problems; physiotherapy is important afterwards |
| Radiotherapy | Skin changes, stiffness, a very small long-term risk of a new tumour |
| Vimseltinib | Swelling around the eyes or face, tiredness, rash, raised muscle enzymes |
| Pexidartinib | Hair colour changes, tiredness, raised liver tests; rare serious liver injury, so regular liver blood tests are needed |
Side effects of the tablets usually settle with dose reduction or a short break. People taking pexidartinib have regular liver blood tests, especially in the first months of treatment.
9. Outlook
| Situation | What to expect |
|---|---|
| Localised TGCT | Usually cured by surgery |
| Diffuse TGCT | Often recurs, in up to half of cases, sometimes several times |
| Long-term joint health | Repeated recurrences and surgery can lead to arthritis and need for joint replacement |
| Life expectancy | Normal; spread to other organs is extremely rare |
10. Living with TGCT
Diffuse TGCT can be a long-term condition. Regular MRI scans, often once a year after surgery, help detect regrowth early.
Physiotherapy keeps the joint moving and the muscles strong. Pain relief, activity adjustments and walking aids may help during flares.
Patient groups for TGCT and specialist sarcoma centres can give advice and information about clinical trials.
Because TGCT mostly affects people of working age, it can affect jobs, sport and family life. Many people find it helpful to plan treatment around these priorities with their team. For example, a CSF1R inhibitor may be preferred to a third operation on the same knee, while surgery may suit someone who wants a one-off treatment.
Keep a diary of swelling, pain and how far you can walk. This makes it easier to judge whether a treatment is working.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is TGCT cancer? | No. It is a benign tumour, though it can be locally aggressive |
| Can it spread? | It does not spread to other organs, except in extremely rare malignant cases |
| Why did it come back after surgery? | Diffuse TGCT is hard to remove completely, as it spreads through the whole joint lining |
| Can I play sport? | Often yes, once symptoms are controlled; ask your team or physiotherapist |
| Will I need a knee replacement? | Only if the joint becomes badly damaged |
12. Questions to ask your care team
- Is my TGCT localised or diffuse, and how much of the joint is involved on MRI?
- Is surgery likely to remove it completely, and what is my risk of recurrence?
- Should surgery be arthroscopic, open or combined?
- Am I a candidate for a CSF1R inhibitor, and how long would I take it?
- What exercises will help after treatment?
- How often will I need MRI scans?
Resources
- WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
- West, R.B. et al. (2006) ‘A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells’, Proceedings of the National Academy of Sciences of the United States of America, 103(3), pp. 690-695.
- Mastboom, M.J.L. et al. (2017) ‘Higher incidence rates than previously known in tenosynovial giant cell tumors’, Acta Orthopaedica, 88(6), pp. 688-694.
- Mastboom, M.J.L. et al. (2019) ‘Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study’, The Lancet Oncology, 20(6), pp. 877-886.
- Tap, W.D. et al. (2019) ‘Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial’, The Lancet, 394(10197), pp. 478-487.
- Gelderblom, H. et al. (2024) ‘Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial’, The Lancet, 403(10445), pp. 2709-2719.
- Xu, H. et al. (2026) ‘Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial’, The Lancet, 407(10533), pp. 1072-1083.
- Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
Prepared by the editorial team, October 2026.